ENOX1

Summary

ENOX1 (ecto-NOX disulfide-thiol exchanger 1, HGNC:25474) is a protein-coding gene on chromosome 13q14.11, encoding Ecto-NOX disulfide-thiol exchanger 1 (Q8TC92). Probably acts as a terminal oxidase of plasma electron transport from cytosolic NAD(P)H via hydroquinones to acceptors at the cell surface.

The protein encoded by this gene is involved in plasma membrane electron transport pathways. The encoded protein has both a hydroquinone (NADH) oxidase activity and a protein disulfide-thiol interchange activity. The two activities cycle with a periodicity of 24 minutes, with one activity being at its peak when the other is at its lowest.

Source: NCBI Gene 55068 — RefSeq curated summary.

At a glance

• GWAS associations: 11
• Clinical variants (ClinVar): 101 total
• MANE Select transcript: NM_001347969

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25474
Approved symbol	ENOX1
Name	ecto-NOX disulfide-thiol exchanger 1
Location	13q14.11
Locus type	gene with protein product
Status	Approved
Aliases	FLJ10094, PIG38, CNOX, cCNOX
Ensembl gene	ENSG00000120658
Ensembl biotype	protein_coding
OMIM	610914
Entrez	55068

Gene structure

Transcript identifiers

Ensembl transcripts: 36 — 35 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000261488, ENST00000482207, ENST00000690772, ENST00000871211, ENST00000871212, ENST00000871213, ENST00000871214, ENST00000871215, ENST00000871216, ENST00000871217, ENST00000871218, ENST00000871219, ENST00000871220, ENST00000871221, ENST00000871222, ENST00000871223, ENST00000941812, ENST00000941813, ENST00000941814, ENST00000941815, ENST00000941816, ENST00000941817, ENST00000941818, ENST00000941819, ENST00000941820, ENST00000941821, ENST00000941822, ENST00000941823, ENST00000941824, ENST00000941825, ENST00000941826, ENST00000941827, ENST00000941828, ENST00000941829, ENST00000941830, ENST00000941831

RefSeq mRNA: 12 — MANE Select: NM_001347969 NM_001127615, NM_001242863, NM_001347963, NM_001347964, NM_001347965, NM_001347966, NM_001347967, NM_001347968, NM_001347969, NM_001347970, NM_001347971, NM_017993

CCDS: CCDS9389

Canonical transcript exons

ENST00000690772 — 17 exons

Exon	Start	End
ENSE00000817260	43322384	43322501
ENSE00000817261	43326419	43326525
ENSE00000817262	43344538	43344750
ENSE00000817263	43355919	43356152
ENSE00000817265	43361279	43361452
ENSE00000817266	43411916	43412053
ENSE00001093157	43298346	43298530
ENSE00001093158	43269470	43269577
ENSE00001093159	43236636	43236738
ENSE00001093160	43224053	43224138
ENSE00001093163	43265398	43265454
ENSE00001181637	43412845	43412988
ENSE00001430606	43484009	43484152
ENSE00003597553	43359851	43360057
ENSE00003927350	43667479	43667544
ENSE00003937238	43213130	43214121
ENSE00003937813	43786652	43786972

Expression profiles

Bgee: expression breadth ubiquitous, 215 present calls, max score 91.84.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.1966 / max 259.1765, expressed in 1028 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
137020	2.2097	682
137021	1.5584	677
137022	1.1803	499
137019	1.0716	440
137018	0.1766	85

Top tissues by expression

283 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	91.84	gold quality
cortical plate	UBERON:0005343	90.25	gold quality
male germ cell	CL:0000015	88.71	gold quality
ganglionic eminence	UBERON:0004023	84.69	gold quality
secondary oocyte	CL:0000655	83.35	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	82.70	gold quality
middle temporal gyrus	UBERON:0002771	82.10	gold quality
oocyte	CL:0000023	81.58	gold quality
Brodmann (1909) area 23	UBERON:0013554	81.46	gold quality
cartilage tissue	UBERON:0002418	80.57	gold quality
ventricular zone	UBERON:0003053	80.25	gold quality
prefrontal cortex	UBERON:0000451	80.24	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	79.95	gold quality
superior frontal gyrus	UBERON:0002661	79.10	gold quality
frontal cortex	UBERON:0001870	78.35	gold quality
neocortex	UBERON:0001950	78.30	gold quality
muscle layer of sigmoid colon	UBERON:0035805	78.01	gold quality
cerebral cortex	UBERON:0000956	77.93	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	77.76	gold quality
spinal cord	UBERON:0002240	77.53	gold quality
anterior cingulate cortex	UBERON:0009835	77.40	gold quality
postcentral gyrus	UBERON:0002581	77.36	gold quality
nucleus accumbens	UBERON:0001882	77.31	gold quality
cingulate cortex	UBERON:0003027	77.29	gold quality
Brodmann (1909) area 9	UBERON:0013540	77.18	gold quality
telencephalon	UBERON:0001893	77.12	gold quality
entorhinal cortex	UBERON:0002728	77.01	gold quality
Ammon’s horn	UBERON:0001954	76.88	gold quality
lower esophagus muscularis layer	UBERON:0035833	76.85	gold quality
lower esophagus	UBERON:0013473	76.77	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-CURD-119	yes	2569.79
E-GEOD-131882	yes	2189.97
E-ANND-3	no	4.01

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NRF1

miRNA regulators (miRDB)

27 targeting ENOX1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-8087	99.90	69.55	1351
HSA-MIR-4496	99.88	68.89	2236
HSA-MIR-323A-3P	99.79	70.30	1739
HSA-MIR-6885-3P	99.75	70.36	3187
HSA-MIR-29B-2-5P	99.67	68.98	1726
HSA-MIR-12122	99.56	69.33	1672
HSA-MIR-513C-5P	99.50	68.42	1730
HSA-MIR-514B-5P	99.50	68.19	1766
HSA-MIR-372-5P	99.41	69.11	2299
HSA-MIR-4318	99.38	66.94	1505
HSA-MIR-520A-5P	99.35	66.72	1632
HSA-MIR-525-5P	99.35	66.85	1615
HSA-MIR-410-3P	99.27	69.98	2457
HSA-MIR-4717-3P	99.06	66.34	1072
HSA-MIR-513B-3P	98.76	68.12	1577
HSA-MIR-7114-5P	98.51	67.87	1349
HSA-MIR-6773-3P	98.17	65.51	1213
HSA-MIR-127-5P	97.78	67.64	869
HSA-MIR-3137	97.26	66.78	761
HSA-MIR-10398-5P	97.12	64.94	1051
HSA-MIR-215-3P	97.02	68.01	1209
HSA-MIR-616-3P	96.82	66.99	784
HSA-MIR-4436B-5P	96.71	68.37	1346
HSA-MIR-582-3P	96.69	67.38	1019

Literature-anchored findings (GeneRIF, showing 4)

• copper-binding capacity, enzymatic activity, and time-keeping (clock) properties (PMID:19055324)
• These results indicate that this sequence variant in ENOX1 may contribute to the familial autoimmune myasthenia in these patients. (PMID:22744667)
• We verified that NRF-1 positively regulates FAM134C and ENOX1, and negatively regulates C3orf10 in human neuroblastoma IMR-32 cells and primary rat cortical neurons. (PMID:23939472)
• Clinical Significance of Serum Kallistatin and ENOX1 Levels in Patients with Coronary Heart Disease. (PMID:32712615)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	enox1	ENSDARG00000060243
mus_musculus	Enox1	ENSMUSG00000022012
rattus_norvegicus	Enox1	ENSRNOG00000047817
drosophila_melanogaster	CG10948	FBGN0036317

Paralogs (1): ENOX2 (ENSG00000165675)

Protein

Protein identifiers

Ecto-NOX disulfide-thiol exchanger 1 — Q8TC92 (reviewed: Q8TC92)

Alternative names: Candidate growth-related and time keeping constitutive hydroquinone [NADH] oxidase, Cell proliferation-inducing gene 38 protein, Constitutive Ecto-NOX

All UniProt accessions (2): A0A024RDT8, Q8TC92

UniProt curated annotations — full annotation on UniProt →

Function. Probably acts as a terminal oxidase of plasma electron transport from cytosolic NAD(P)H via hydroquinones to acceptors at the cell surface. Hydroquinone oxidase activity alternates with a protein disulfide-thiol interchange/oxidoreductase activity which may control physical membrane displacements associated with vesicle budding or cell enlargement. The activities oscillate with a period length of 24 minutes and play a role in control of the ultradian cellular biological clock.

Subcellular location. Cell membrane. Secreted. Extracellular space.

Tissue specificity. Expressed in lymphocyte cells, breast and breast cancer (at protein level). Found in the sera of cancer patients with a wide variety of cancers including breast, prostate, lung and ovarian cancers, leukemias, and lymphomas. Found also in the serum of healthy volunteers or patients with disorders other than cancer. Probably shed into serum by cancer cells.

Activity regulation. Not inhibited by the antitumor sulfonylurea LY181984, the vabilloid capsaicin, and retinoids.

Similarity. Belongs to the ENOX family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8TC92-1	1	yes
Q8TC92-2	2

RefSeq proteins (12): NP_001121087, NP_001229792, NP_001334892, NP_001334893, NP_001334894, NP_001334895, NP_001334896, NP_001334897, NP_001334898, NP_001334899, NP_001334900, NP_060463 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000504	RRM_dom	Domain
IPR012677	Nucleotide-bd_a/b_plait_sf	Homologous_superfamily
IPR034140	ENOX_RRM	Domain
IPR035979	RBD_domain_sf	Homologous_superfamily
IPR038876	ENOX1/2	Family
IPR056611	ENOX1/2_dom	Domain

Pfam: PF00076, PF23267

UniProt features (10 total): splice variant 3, coiled-coil region 2, sequence conflict 2, chain 1, domain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8TC92-F1	75.26	0.37

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 87 (showing top): FREAC2_01, GCANCTGNY_MYOD_Q6, GOCC_CELL_SURFACE, AREB6_01, YY1_Q6, EVI1_05, YY1_02, MODULE_480, ONDER_CDH1_TARGETS_2_UP, GATA1_04, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_NAD_P_H, chr13q14, MODULE_427, TGGAAA_NFAT_Q4_01, GCCATNTTG_YY1_Q6

GO Biological Process (2): ultradian rhythm (GO:0007624), rhythmic process (GO:0048511)

GO Molecular Function (6): RNA binding (GO:0003723), protein disulfide isomerase activity (GO:0003756), NADH dehydrogenase activity (GO:0003954), nucleic acid binding (GO:0003676), protein binding (GO:0005515), oxidoreductase activity (GO:0016491)

GO Cellular Component (4): extracellular region (GO:0005576), plasma membrane (GO:0005886), external side of plasma membrane (GO:0009897), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	2
cellular anatomical structure	2
rhythmic process	1
biological_process	1
nucleic acid binding	1
intramolecular oxidoreductase activity, transposing S-S bonds	1
catalytic activity, acting on a protein	1
oxidoreductase activity, acting on NAD(P)H	1
catalytic activity	1
membrane	1
cell periphery	1
plasma membrane	1
cell surface	1
side of membrane	1

Protein interactions and networks

STRING

616 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ENOX1	CTIF	O43310	587
ENOX1	OR5M11	Q96RB7	540
ENOX1	C10orf71	Q711Q0	518
ENOX1	PMFBP1	Q8TBY8	487
ENOX1	CCDC126	Q96EE4	477
ENOX1	TMEM161B	Q8NDZ6	460
ENOX1	LHPP	Q9H008	460
ENOX1	TIGD4	Q8IY51	447
ENOX1	ARHGAP28	Q9P2N2	447
ENOX1	ASB17	Q8WXJ9	437
ENOX1	L3MBTL2	Q969R5	435
ENOX1	TOM1L1	O75674	435
ENOX1	OLFM4	Q6UX06	432
ENOX1	OR5AR1	Q8NGP9	429
ENOX1	DPY19L3	Q6ZPD9	422

IntAct

44 interactions, top by confidence:

A	B	Type	Score
ENOX1	TRIM43	psi-mi:“MI:0915”(physical association)	0.720
ZMYND19	ENOX1	psi-mi:“MI:0915”(physical association)	0.720
TRIM43	ENOX1	psi-mi:“MI:0915”(physical association)	0.720
ENOX1	ZMYND19	psi-mi:“MI:0915”(physical association)	0.720
LNX1	ENOX1	psi-mi:“MI:0915”(physical association)	0.670
ENOX1	LNX1	psi-mi:“MI:0915”(physical association)	0.670
ENOX1	SDCBP	psi-mi:“MI:0915”(physical association)	0.560
ENOX1	ENOX2	psi-mi:“MI:0915”(physical association)	0.560
ENOX1	GORASP2	psi-mi:“MI:0915”(physical association)	0.560
SDCBP	ENOX1	psi-mi:“MI:0915”(physical association)	0.560
GORASP2	ENOX1	psi-mi:“MI:0915”(physical association)	0.560
	ENOX1	psi-mi:“MI:0915”(physical association)	0.560
RPP25L	RPP40	psi-mi:“MI:0914”(association)	0.530
SULT1E1	ENOX1	psi-mi:“MI:0915”(physical association)	0.370
ENOX1	NIF3L1	psi-mi:“MI:0915”(physical association)	0.370
ZBTB16	ENOX1	psi-mi:“MI:0915”(physical association)	0.370
ENOX2	ENOX1	psi-mi:“MI:0915”(physical association)	0.370
Mis12		psi-mi:“MI:0914”(association)	0.350
Eef1a1	ERLIN2	psi-mi:“MI:0914”(association)	0.350
M		psi-mi:“MI:0914”(association)	0.350
SRSF4		psi-mi:“MI:0914”(association)	0.350
SRSF5	FBLL1	psi-mi:“MI:0914”(association)	0.350

BioGRID (26): ENOX1 (Two-hybrid), ENOX1 (Two-hybrid), ENOX1 (Two-hybrid), ZMYND19 (Two-hybrid), TRIM43 (Two-hybrid), ENOX1 (Affinity Capture-MS), ENOX1 (Two-hybrid), NIF3L1 (Two-hybrid), LNX1 (Two-hybrid), ENOX1 (Two-hybrid), ENOX1 (Two-hybrid), ENOX1 (Affinity Capture-MS), ENOX1 (Affinity Capture-MS), ENOX1 (Affinity Capture-RNA), ENOX1 (Affinity Capture-RNA)

ESM2 similar proteins: A5PJV0, A7YY73, F1QW76, O15525, O43150, O54790, O54791, O57337, O60675, P13096, P13097, P13098, P35428, P50538, P97496, Q01068, Q01069, Q01070, Q01071, Q01664, Q04666, Q05195, Q07291, Q07E41, Q108T9, Q14469, Q14582, Q16206, Q16520, Q3ZBG4, Q5FWS6, Q5PPM5, Q61827, Q674X7, Q6IRB2, Q6PBD4, Q76MX4, Q7Z3E5, Q8AVU4, Q8BHR2

Diamond homologs: A6NDY0, B0BNE4, B1WC40, B7P877, O13741, O14327, O75494, O89086, O93235, P07909, P40561, P41891, P42696, P48810, P52298, P53883, P98179, Q00916, Q02926, Q08208, Q09295, Q09301, Q15056, Q16206, Q177H0, Q1HE01, Q1JPH6, Q28165, Q28ZX3, Q3MHY8, Q3ZBJ1, Q499V6, Q54ZS8, Q56JZ7, Q5M9F1, Q5RBR8, Q5XFR0, Q5XI72, Q6C2Q7, Q6CKV6

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
NRF1	“up-regulates quantity by expression”	ENOX1	“transcriptional regulation”
NRF1	up-regulates	ENOX1

Disease & clinical

Clinical variants and AI predictions

ClinVar

101 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	86
Likely benign	6
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

7466 predictions. Top by Δscore:

Variant	Effect	Δscore
13:43236630:CCTTA:C	donor_loss	1.0000
13:43236631:CTTAC:C	donor_loss	1.0000
13:43236632:TTACC:T	donor_loss	1.0000
13:43236633:TACC:T	donor_loss	1.0000
13:43236634:A:AC	donor_gain	1.0000
13:43236634:ACCTA:A	donor_loss	1.0000
13:43236635:C:CC	donor_gain	1.0000
13:43236635:C:T	donor_loss	1.0000
13:43269463:CACT:C	donor_loss	1.0000
13:43269464:ACTT:A	donor_loss	1.0000
13:43269466:TT:T	donor_loss	1.0000
13:43269467:TAC:T	donor_loss	1.0000
13:43269468:A:AC	donor_gain	1.0000
13:43269468:A:C	donor_loss	1.0000
13:43269469:C:CC	donor_gain	1.0000
13:43269573:AATTG:A	acceptor_gain	1.0000
13:43269575:TTG:T	acceptor_gain	1.0000
13:43269576:TG:T	acceptor_gain	1.0000
13:43298341:GGTAC:G	donor_loss	1.0000
13:43298343:TAC:T	donor_loss	1.0000
13:43298345:CCTG:C	donor_gain	1.0000
13:43298526:CAGGG:C	acceptor_gain	1.0000
13:43298527:AGGG:A	acceptor_gain	1.0000
13:43298528:GGG:G	acceptor_gain	1.0000
13:43298529:GG:G	acceptor_gain	1.0000
13:43298531:C:CA	acceptor_loss	1.0000
13:43298531:C:CC	acceptor_gain	1.0000
13:43298532:T:C	acceptor_loss	1.0000
13:43322379:ATTAC:A	donor_loss	1.0000
13:43322497:AGCTC:A	acceptor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000004372 (13:43444117 C>G), RS1000009200 (13:43773390 C>T), RS1000010382 (13:43631847 G>C), RS1000012696 (13:43411210 TAGAGAGA>T), RS1000017495 (13:43320976 G>C), RS1000023233 (13:43277957 G>A), RS1000024226 (13:43725133 A>C), RS1000026741 (13:43456086 T>C), RS1000038481 (13:43323650 C>T), RS1000045351 (13:43217962 C>T), RS1000049035 (13:43713175 T>A), RS1000051149 (13:43406166 G>C), RS1000061790 (13:43397692 A>T), RS1000070851 (13:43406362 C>A), RS1000071593 (13:43573402 T>C,G)

Disease associations

OMIM: gene MIM:610914 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

11 associations (top):

Study	Trait	p-value
GCST001476_12	Response to tocilizumab in rheumatoid arthritis	2.000000e-07
GCST001798_16	End-stage coagulation	2.000000e-09
GCST001850_22	Major depressive disorder	2.000000e-06
GCST001850_45	Major depressive disorder	4.000000e-07
GCST002927_3	Mercury levels	6.000000e-06
GCST003992_15	Photic sneeze reflex	4.000000e-09
GCST005839_43	Depression	3.000000e-08
GCST008358_2	Response to cognitive-behavioural therapy in anxiety and major depressive disorders	5.000000e-06
GCST009600_7	Anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy)	1.000000e-08
GCST010605_11	Parent of origin effect on receptive language ability (paternal)	5.000000e-06
GCST011768_10	Schizophrenia	5.000000e-09

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0007887	autosomal dominant compelling helio-ophthalmic outburst syndrome
EFO:0007820	cognitive behavioural therapy
EFO:0005686	receptive language perception
EFO:0005939	parental genotype effect measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

32 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression, decreases methylation	8
Aflatoxin B1	affects expression, affects methylation, decreases expression, decreases methylation	7
Benzo(a)pyrene	affects methylation, decreases expression, increases methylation	4
lasiocarpine	decreases expression	2
methyleugenol	decreases expression	2
N-Nitrosopyrrolidine	decreases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
propionaldehyde	increases expression	1
bisphenol A	decreases methylation	1
trichostatin A	increases expression	1
sodium arsenite	increases expression	1
perfluorooctanoic acid	increases expression	1
2-palmitoylglycerol	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
clothianidin	increases expression	1
quinocetone	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
bisphenol S	decreases methylation	1
Decitabine	decreases expression, affects reaction	1
Panobinostat	affects cotreatment, increases expression	1
Acetaminophen	increases expression	1
alpha-Chlorohydrin	decreases expression	1
Carbamazepine	affects expression	1
Demecolcine	increases expression	1
Dexamethasone	decreases expression	1
Doxorubicin	decreases expression	1
Melphalan	decreases expression	1
Phthalic Acids	increases methylation	1
Tobacco Smoke Pollution	decreases expression	1
Vincristine	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer